Why the study?
Does polio vaccination (OPV, IPV, or combination) provide adequate antibody levels against poliovirus in the Hungarian population?
Does polio vaccination (OPV, IPV, or combination) provide adequate antibody levels against poliovirus in the Hungarian population?
Both IPV and OPV vaccines provide adequate seroconversion against poliovirus in the Hungarian population, and maternal antibodies are present in most newborns.
Answers are grounded in this paper and cite their sources.
Supports polio vaccination programs in Hungary; leaves open durability of immunity and generalizability beyond this cross-sectional sample.
During clinical trials, samples from Hungarian patients of different age groups were tested for antibodies against all 3 serotypes of poliovirus, a member of Picornaviridae family. During the virus neutralization serological test, blood samples were titrated using permanent virus concentration. Based on the cythopathic effect observed under a light microscope, the antibody level of the patient was assessed. The 100 people examined were classified into 5 groups based on age and type of original vaccine: I. Newborns, no vaccination given; II. Immunosuppressed patients; III. Born before 1986, received only OPV vaccine; IV. Born between 1992-2005, received a combination of OPV and IPV vaccines; V. Born after 2006, received only IPV vaccine. Results show that vaccination coverage meets all the criteria. None of the immunized persons was seronegative to all three polioviruses. Both IPV and OPV vaccines are effective against poliovirus. Blood samples from newborn babies with no immunization were also examined. Results show that most newborns have maternal antibodies in their blood. Results of group II show that immunosuppression does not have a negative influence on blood antibody levels against polioviruses. In spite of the low number of samples, our results show that seroconversion after immunization in the Hungarian population is adequate. For more accurate results about vaccination coverage in the population, further trials would be necessary.
No takes yet. Share an insight, caveat, or question.
Farkas et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: